Cargando…

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy

Epithelial ovarian cancer remains the most lethal female malignancy despite options for systemic therapy and the emergence of targeted therapies. Although initial response to therapy is observed, recurrence and ultimately chemoresistance result in overall therapeutic failure. This pattern has been e...

Descripción completa

Detalles Bibliográficos
Autores principales: Summey, Rebekah, Uyar, Denise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511803/
https://www.ncbi.nlm.nih.gov/pubmed/36176755
http://dx.doi.org/10.20517/cdr.2021.146
_version_ 1784797718156148736
author Summey, Rebekah
Uyar, Denise
author_facet Summey, Rebekah
Uyar, Denise
author_sort Summey, Rebekah
collection PubMed
description Epithelial ovarian cancer remains the most lethal female malignancy despite options for systemic therapy and the emergence of targeted therapies. Although initial response to therapy is observed, recurrence and ultimately chemoresistance result in overall therapeutic failure. This pattern has been evident with platinum therapy since the 1980s. Significant excitement surrounded the approval of poly (ADP-ribose) polymerase inhibition (PARPi) as a novel therapeutic option, especially with the advent of personalized medicine, but resistance has similarly developed to these treatments. Novel agents are constantly being sought, but if the obstacle of chemoresistance remains, the durability of responses will remain tenuous. Unraveling the multifactorial mechanisms of platinum and PARPi resistance is increasingly important as a therapeutic failure with current strategies is almost assured. Focusing greater efforts on expanding the current understanding of the complex nature of platinum and PARPi chemoresistance has tremendous potential to improve clinical outcomes.
format Online
Article
Text
id pubmed-9511803
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-95118032022-09-28 Ovarian cancer resistance to PARPi and platinum-containing chemotherapy Summey, Rebekah Uyar, Denise Cancer Drug Resist Commentary Epithelial ovarian cancer remains the most lethal female malignancy despite options for systemic therapy and the emergence of targeted therapies. Although initial response to therapy is observed, recurrence and ultimately chemoresistance result in overall therapeutic failure. This pattern has been evident with platinum therapy since the 1980s. Significant excitement surrounded the approval of poly (ADP-ribose) polymerase inhibition (PARPi) as a novel therapeutic option, especially with the advent of personalized medicine, but resistance has similarly developed to these treatments. Novel agents are constantly being sought, but if the obstacle of chemoresistance remains, the durability of responses will remain tenuous. Unraveling the multifactorial mechanisms of platinum and PARPi resistance is increasingly important as a therapeutic failure with current strategies is almost assured. Focusing greater efforts on expanding the current understanding of the complex nature of platinum and PARPi chemoresistance has tremendous potential to improve clinical outcomes. OAE Publishing Inc. 2022-06-22 /pmc/articles/PMC9511803/ /pubmed/36176755 http://dx.doi.org/10.20517/cdr.2021.146 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Commentary
Summey, Rebekah
Uyar, Denise
Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
title Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
title_full Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
title_fullStr Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
title_full_unstemmed Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
title_short Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
title_sort ovarian cancer resistance to parpi and platinum-containing chemotherapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511803/
https://www.ncbi.nlm.nih.gov/pubmed/36176755
http://dx.doi.org/10.20517/cdr.2021.146
work_keys_str_mv AT summeyrebekah ovariancancerresistancetoparpiandplatinumcontainingchemotherapy
AT uyardenise ovariancancerresistancetoparpiandplatinumcontainingchemotherapy